Cystic fibrosis in Tuscany: evolution of newborn screening strategies over time to the present.
CFTR allelic heterogeneity
Cystic fibrosis
DNA molecular analysis
Immunoreactive trypsinogen
Newborn screening for cystic fibrosis CF NBS
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
06 Jan 2021
06 Jan 2021
Historique:
received:
08
07
2020
accepted:
04
12
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
3
2
2021
Statut:
epublish
Résumé
Cystic fibrosis (CF) is a life-threatening disease affecting about 1:3000 newborns in Caucasian populations. The introduction of newborn screening for cystic fibrosis (CF NBS) has improved the clinical outcomes of individuals with CF through early diagnosis and early treatment. NBS strategies have been implemented over time. CF NBS was introduced extensively in 1984 in Tuscany, a region with 3.7 million people, characterized by a high allelic heterogeneity of CFTR gene. The aim of the study is to present the results from 34 years (1984-2018) of CF NBS, retrospectively evaluating the sensitivity, specificity and predictive values of the tests. In particular, we studied the impact of the introduction of DNA molecular analysis in NBS in a region with high allelic heterogeneity, such as Tuscany. Over these 34 years, 919,520 neonates were screened, using four different NBS strategies. From 1984 to 1991, CF NBS was performed by the determination of albumin on dried meconium (sensitivity 68.75%; specificity 99.82%). Subsequently, the analysis of immunoreactive trypsinogen on a blood spot was adopted as CF NBS protocol (sensitivity 83.33%; specificity 99.77%). From 1992 to 2010, this strategy was associated with lactase meconium dosage: IRT1/IRT2 + LACT protocol (sensitivity 87.50%; specificity 99.82%). From 2011, when the existing algorithm was integrated by analysis of CF causing variants of the CFTR gene (IRT1/IRT2 + LACT + IRT1/DNA protocol), a substantial improvement in sensitivity was seen (senisitivity 96.15%; specificity 99.75%). Other improved parameters with DNA analysis in the NBS programme, compared with the previous method, were the diagnosis time (52 days vs. 38 days) and the recall rate (0.58 to 0.38%). The inclusion of DNA analysis in the NBS was a fundamental step in improving sensitivity, even in a region with high allelic variability.
Sections du résumé
BACKGROUND
BACKGROUND
Cystic fibrosis (CF) is a life-threatening disease affecting about 1:3000 newborns in Caucasian populations. The introduction of newborn screening for cystic fibrosis (CF NBS) has improved the clinical outcomes of individuals with CF through early diagnosis and early treatment. NBS strategies have been implemented over time. CF NBS was introduced extensively in 1984 in Tuscany, a region with 3.7 million people, characterized by a high allelic heterogeneity of CFTR gene.
AIM AND METHODS
OBJECTIVE
The aim of the study is to present the results from 34 years (1984-2018) of CF NBS, retrospectively evaluating the sensitivity, specificity and predictive values of the tests. In particular, we studied the impact of the introduction of DNA molecular analysis in NBS in a region with high allelic heterogeneity, such as Tuscany.
RESULTS
RESULTS
Over these 34 years, 919,520 neonates were screened, using four different NBS strategies. From 1984 to 1991, CF NBS was performed by the determination of albumin on dried meconium (sensitivity 68.75%; specificity 99.82%). Subsequently, the analysis of immunoreactive trypsinogen on a blood spot was adopted as CF NBS protocol (sensitivity 83.33%; specificity 99.77%). From 1992 to 2010, this strategy was associated with lactase meconium dosage: IRT1/IRT2 + LACT protocol (sensitivity 87.50%; specificity 99.82%). From 2011, when the existing algorithm was integrated by analysis of CF causing variants of the CFTR gene (IRT1/IRT2 + LACT + IRT1/DNA protocol), a substantial improvement in sensitivity was seen (senisitivity 96.15%; specificity 99.75%). Other improved parameters with DNA analysis in the NBS programme, compared with the previous method, were the diagnosis time (52 days vs. 38 days) and the recall rate (0.58 to 0.38%).
CONCLUSION
CONCLUSIONS
The inclusion of DNA analysis in the NBS was a fundamental step in improving sensitivity, even in a region with high allelic variability.
Identifiants
pubmed: 33407736
doi: 10.1186/s13052-020-00948-8
pii: 10.1186/s13052-020-00948-8
pmc: PMC7788805
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Références
Clin Biochem. 2013 Jan;46(1-2):133-8
pubmed: 23010448
J Pediatr. 2017 Feb;181S:S45-S51.e1
pubmed: 28129812
Eur J Hum Genet. 2010 Oct;18(10):1084-9
pubmed: 20512163
Arch Dis Child. 1974 Aug;49(8):597-601
pubmed: 4213834
J Pediatr. 2017 Feb;181S:S33-S44.e2
pubmed: 28129810
Pediatrics. 2009 Feb;123(2):e338-46
pubmed: 19171585
Acta Paediatr. 1997 May;86(5):497-502
pubmed: 9183489
J Dev Behav Pediatr. 1992 Jun;13(3):181-6
pubmed: 1613113
J Pediatr. 2009 Nov;155(5):618-22
pubmed: 19540513
Ital J Pediatr. 2018 Jan 3;44(1):2
pubmed: 29298718
Am J Hum Genet. 1993 Mar;52(3):616-26
pubmed: 7680526
Nat Genet. 1994 Jun;7(2):169-75
pubmed: 7920636
J Cyst Fibros. 2018 May;17(3):306-315
pubmed: 29572018
J Pediatr. 2017 Feb;181S:S4-S15.e1
pubmed: 28129811
Science. 1989 Sep 8;245(4922):1066-73
pubmed: 2475911
Pediatrics. 1990 Jun;85(6):1001-7
pubmed: 2187173
Lancet. 2007 Apr 7;369(9568):1146-7
pubmed: 17416243
Lancet Respir Med. 2020 Jan;8(1):65-124
pubmed: 31570318
J Pediatr. 1983 Mar;102(3):383-7
pubmed: 6827410
Arch Dis Child. 2008 Apr;93(4):357-8
pubmed: 18356397
J Cyst Fibros. 2017 Mar;16(2):207-213
pubmed: 28043799
J Cyst Fibros. 2007 Jan;6(1):57-65
pubmed: 16870510
J Cyst Fibros. 2019 Jul;18(4):484-490
pubmed: 31005549
Lancet Respir Med. 2016 Aug;4(8):653-661
pubmed: 27053341
Diagnostics (Basel). 2020 Jul 01;10(7):
pubmed: 32630227
J Cyst Fibros. 2018 Mar;17(2):153-178
pubmed: 29506920
Expert Rev Respir Med. 2015 Oct;9(5):619-31
pubmed: 26366807
Epidemiol Prev. 2019 Jul-Aug;43(4S1):1-36
pubmed: 31370382